These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
92 related articles for article (PubMed ID: 22724220)
41. Effect of statins therapy prior to percutaneous coronary intervention. Luo J; Xu L; Yu T; Li J J Interv Cardiol; 2012 Apr; 25(2):156-62. PubMed ID: 22248354 [TBL] [Abstract][Full Text] [Related]
42. [Controversies regarding the use of statins in the acute coronary syndrome]. Camps D Med Intensiva; 2010; 34(6):432; author reply 432-3. PubMed ID: 20538377 [No Abstract] [Full Text] [Related]
43. Pregnancy associated plasma protein-A (PAPP-A) is not a marker of the vulnerable atherosclerotic plaque. Iversen K; Teisner A; Dalager S; Olsen KE; Floridon C; Teisner B Clin Biochem; 2011 Mar; 44(4):312-8. PubMed ID: 21185276 [TBL] [Abstract][Full Text] [Related]
44. High-density lipoproteins may offer a more promising route to statin therapy. Coaker H Future Cardiol; 2014 Mar; 10(2):164. PubMed ID: 24883441 [No Abstract] [Full Text] [Related]
45. Biomarkers, C-reactive proteins and statins in acute coronary syndromes. Ray KK Fundam Clin Pharmacol; 2007 Nov; 21 Suppl 2():31-3. PubMed ID: 18001319 [TBL] [Abstract][Full Text] [Related]
49. Management of dyslipidemia in patients with complicated metabolic syndrome. Davidson MH Am J Cardiol; 2005 Aug; 96(4A):22E-25E. PubMed ID: 16098839 [TBL] [Abstract][Full Text] [Related]
50. Is clonal hematopoiesis a new risk factor for cardiovascular diseases?: Clinical and experimental evidences. Páramo Fernandez JA Med Clin (Barc); 2018 Sep; 151(5):207-209. PubMed ID: 29802011 [No Abstract] [Full Text] [Related]
51. Statins after acute coronary syndrome: a missed opportunity. Roth GA Heart; 2014 May; 100(10):752-3. PubMed ID: 24526752 [No Abstract] [Full Text] [Related]
52. [Pathogenesis of acute coronary syndrome: mechanism of plaque rupture]. Hiro T Nihon Rinsho; 2011 Nov; 69 Suppl 9():286-93. PubMed ID: 22724217 [No Abstract] [Full Text] [Related]
53. Assessing vulnerable plaque: is shear stress enough? Tousoulis D; Papageorgiou N; Synetos A; Stefanadis C Int J Cardiol; 2014; 172(1):e135-8. PubMed ID: 24485228 [No Abstract] [Full Text] [Related]
54. Rationale and design of the Hellenic Registry of Clinical events and Adherence to Lipid LowerINg therapy In aCUte coronary Syndrome (CALLINICUS-Hellas Registry). Rallidis LS; Tasoulas D; Leventis I; Malkots B; Kladou E; Zapantiotis D; Theofilatos A; Zormpas G; Kalogeras P; Betsis C; Lykoudis A; Tsamoulis D; Kalantzis C; Miliotou A; Daios S; Delakis I; Manolis G; Papathanasiou KA; Vlachopoulos C Hellenic J Cardiol; 2022; 66():84-86. PubMed ID: 35623541 [No Abstract] [Full Text] [Related]
55. A Novel Molecular Pathway of Plaque Vulnerability Reveals a Cholesterol-Independent Effect of Statins and Supports Inflammation as a Therapeutic Target. Mury P; Dupuis J; Thorin E Can J Cardiol; 2020 Nov; 36(11):1710-1713. PubMed ID: 32315602 [No Abstract] [Full Text] [Related]
56. How to identify HIV-infected individuals at risk for atherosclerotic events? Boccara F; Cohen A AIDS; 2014 Sep; 28(14):2153-5. PubMed ID: 25265079 [No Abstract] [Full Text] [Related]
57. Changes in Plaque Composition and the Pleiotropic Effects of Statins. Mascitelli L; Goldstein MR J Am Coll Cardiol; 2016 Sep; 68(11):1250-1251. PubMed ID: 27609690 [No Abstract] [Full Text] [Related]